각막 질환 시장(2025년) : 국가별 질환 유병률 데이터

Market Scope's "2025 Corneal Disease Model" delivers detailed, country-level insight into corneal disease prevalence worldwide, with age-specific estimates and five-year forecasts across nine corneal indications for every country with a population over one million.

Built on the latest clinical literature and global demographic projections, this proprietary model provides a consistent, forward-looking view of corneal disease prevalence. The model can be customized by geography and disease category to support strategic planning, including market sizing, evaluation of target populations for clinical- and commercial-stage products, and analysis of how corneal disease demographics are expected to evolve over time.

Contents:

The 2024 Corneal Disease Model provides comprehensive, country-level prevalence data across 228 countries with populations over one million, capturing the full range of corneal conditions that drive both clinical demand and emerging therapeutic development. Coverage spans degenerative, infectious, traumatic, and congenital diseases, offering a unified view of global corneal disease prevalence.

Conditions covered include:

• Ectatic diseases: keratoconus and other corneal ectasias
• Corneal dystrophies: Fuchs' dystrophy and other inherited dystrophies
• Acquired corneal disease: trauma-related and syndromic conditions
• Infectious corneal disease: trachoma and other infectious etiologies
• Congenital corneal conditions: plana, dermoids, and structural malformations
• Other corneal disorders: keratitis, pterygium, measles-related disease, and related conditions

Methodology:

Market Scope utilizes proprietary demographic models and the latest clinical research to estimate diseased populations at the country level. The Corneal Disease Model integrates data from more than 100 peer-reviewed clinical and epidemiologic studies, with each input carefully evaluated and weighted based on study design, sample size, age stratification, geographic relevance, and scope. These data are then aligned with country-specific population structures and demographic projections to produce consistent, comparable prevalence estimates across markets.